Earlier this month, the Sabin Vaccine Institute invited individuals to participate in a survey of current knowledge and practices related to the Global Vaccine Action Plan (GVAP).

Special Projects

 
Sabin works with partners around the world, including the World Health Organization (WHO), the Pan American Health Organization (PAHO), Fundação Oswaldo Cruz (FIOCRUZ) and the Bill & Melinda Gates Foundation, to convene symposiums that have brought together more than 2,400 of the world’s global health stakeholders to work on advancing vaccination as a cost-effective weapon in public health.
 
Sabin is dedicated to reducing the burden and impact of infectious diseases through the use of new and underutilized vaccines.
For many people throughout the world, the bite of a mosquito is nothing more than a common annoyance. But for individuals living in dengue endemic countries such an annoyance can quickly turn into a life threatening condition.

The Sabin Vaccine Institute is interested in your feedback on the Decade of Vaccines Global Vaccine Action Plan (GVAP).

Novartis and Biological E agree to deliver affordable vaccines for typhoid and paratyphoid A fevers to developing world

Novartis today announced that it has entered into a development and licensing agreement with Biological E Limited (BioE), a biopharmaceutical company based in India, for two vaccines to protect against typhoid and paratyphoid fevers. The agreement advances the Novartis goal to deliver accessible and affordable vaccines that address unmet medical need in endemic regions.

Continue reading. 

Pages

Subscribe to RSS - Vaccine Advocacy and Education